Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

(2017) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

O-0029 * FOLFIRI PLUS CETUXIMAB VERSUS FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF KRAS-WILDTYPE METASTATIC COLORECTAL CANCER: GERMAN AIO STUDY KRK-0306 (FIRE-3)

(2013) D. Modest et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

(2012) Mi-Jung Kim et al.   BMC CANCER

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

(2012) Y. Imamura et al.   CLINICAL CANCER RESEARCH

Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

(2012) Sabine Tejpar et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools

(2011) F. A. San Lucas et al.   BIOINFORMATICS

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE